Classification/NN
of/IN
Genes/NNS
Based/VBN
on/IN
Age-Related/JJ
Differential/JJ
Expression/NN
in/IN
Breast/NN
Cancer/NN
./.
====================
Transcriptome/DT
analysis/NN
has/VBZ
been/VBN
widely/RB
used/VBN
to/TO
make/VB
biomarker/NN
panels/NNS
to/TO
diagnose/VB
cancers/NNS
./.
====================
In/IN
breast/NN
cancer/NN
,/,
the/DT
age/NN
of/IN
the/DT
patient/NN
has/VBZ
been/VBN
known/VBN
to/TO
be/VB
associated/VBN
with/IN
clinical/JJ
features/NNS
./.
====================
As/IN
clinical/JJ
transcriptome/JJ
data/NNS
have/VBP
accumulated/VBN
significantly/RB
,/,
we/PRP
classified/VBD
all/DT
human/JJ
genes/NNS
based/VBN
on/IN
age-specific/JJ
differential/JJ
expression/NN
between/IN
normal/JJ
and/CC
breast/NN
cancer/NN
cells/NNS
using/VBG
public/JJ
data/NNS
./.
====================
We/PRP
retrieved/VBD
the/DT
values/NNS
for/IN
gene/NN
expression/NN
levels/NNS
in/IN
breast/NN
cancer/NN
and/CC
matched/VBN
normal/JJ
cells/NNS
from/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
./.
====================
We/PRP
divided/VBD
genes/NNS
into/IN
two/CD
classes/NNS
by/IN
paired/JJ
t/NN
test/NN
without/IN
considering/VBG
age/NN
in/IN
the/DT
first/JJ
classification/NN
./.
====================
We/PRP
carried/VBD
out/RP
a/DT
secondary/JJ
classification/NN
of/IN
genes/NNS
for/IN
each/DT
class/NN
into/IN
eight/CD
groups/NNS
,/,
based/VBN
on/IN
the/DT
patterns/NNS
of/IN
the/DT
p-values/NNS
,/,
which/WDT
were/VBD
calculated/VBN
for/IN
each/DT
of/IN
the/DT
three/CD
age/NN
groups/NNS
we/PRP
defined/VBD
./.
====================
Through/IN
this/DT
two-step/JJ
classification/NN
,/,
gene/NN
expression/NN
was/VBD
eventually/RB
grouped/VBD
into/IN
16/CD
classes/NNS
./.
====================
We/PRP
showed/VBD
that/IN
this/DT
classification/NN
method/NN
could/MD
be/VB
applied/VBN
to/TO
establish/VB
a/DT
more/RBR
accurate/JJ
prediction/NN
model/NN
to/TO
diagnose/VB
breast/NN
cancer/NN
by/IN
comparing/VBG
the/DT
performance/NN
of/IN
prediction/NN
models/NNS
with/IN
different/JJ
combinations/NNS
of/IN
genes/NNS
./.
====================
We/PRP
expect/VBP
that/DT
our/PRP$
scheme/NN
of/IN
classification/NN
could/MD
be/VB
used/VBN
for/IN
other/JJ
types/NNS
of/IN
cancer/NN
data/NNS
./.
====================
Breast/NN
cancer/NN
is/VBZ
known/VBN
to/TO
one/CD
of/IN
the/DT
leading/VBG
causes/VBZ
of/IN
cancer/NN
death/NN
among/IN
females/NNS
[/(
1/CD
]/)
./.
====================
A/DT
massive/JJ
number/NN
of/IN
research/NN
studies/NNS
on/IN
the/DT
genomic/JJ
characterization/NN
of/IN
breast/NN
cancer/NN
,/,
particularly/RB
the/DT
discovery/NN
of/IN
differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
,/,
have/VBP
revealed/VBN
clinically/RB
relevant/JJ
molecular/JJ
subtypes/NNS
[/(
2/CD
]/)
,/,
which/WDT
has/VBZ
increased/VBN
the/DT
accuracy/NN
of/IN
the/DT
prognosis/NN
[/(
3–5/CD
]/)
and/CC
has/VBZ
resulted/VBD
in/IN
successful/JJ
targeted/VBN
therapy/NN
[/(
6/CD
,/,
7/CD
]/)
./.
====================
During/IN
recent/JJ
decades/NNS
,/,
resources/VBZ
based/VBN
on/IN
high-throughput/JJ
sequencing/NN
technologies/NNS
,/,
such/JJ
as/IN
The/DT
Cancer/NN
Genome/NN
Atlas/IN
(/(
TCGA/NN
)/)
[/(
8/CD
]/)
and/CC
International/JJ
Cancer/NN
Genome/NN
Consortium/NN
(/(
ICGC/NN
)/)
[/(
9/CD
]/)
,/,
have/VBP
facilitated/VBN
more/RBR
accurate/JJ
detection/NN
of/IN
DEGs/NNS
and/CC
cancer/NN
driver/RB
genes/NNS
./.
====================
The/DT
identification/NN
of/IN
DEGs/NNS
is/VBZ
prominent/JJ
,/,
in/IN
that/DT
it/PRP
leads/VBZ
to/TO
more/RBR
accurate/JJ
subtyping/VBG
and/CC
more/RBR
precise/JJ
treatment/NN
for/IN
various/JJ
types/NNS
of/IN
cancers/NNS
./.
====================
In/IN
transcriptome/JJ
analysis/NN
based/VBN
on/IN
microarray/NN
[/(
10/CD
]/)
or/CC
RNA/NN
sequencing/NN
[/(
11/CD
]/)
by/IN
next-generation/NN
sequencing/NN
,/,
DEGs/NNS
are/VBP
usually/RB
identified/VBN
by/IN
statistical/JJ
tests/NNS
,/,
such/JJ
as/IN
t/NN
test/NN
,/,
nonparametric/JJ
test/NN
,/,
and/CC
Bayesian/JJ
models/NNS
[/(
12/CD
]/)
./.
====================
Subsequent/JJ
analysis/NN
of/IN
pathways/NNS
and/CC
functional/JJ
enrichment/JJ
tests/NNS
for/IN
DEGs/NNS
are/VBP
performed/VBN
to/TO
increase/VB
the/DT
understanding/NN
of/IN
molecular/JJ
mechanisms/NNS
[/(
13/CD
]/)
./.
====================
In/IN
the/DT
case/NN
of/IN
breast/NN
cancer/NN
,/,
it/PRP
is/VBZ
well/RB
known/VBN
that/IN
molecular/JJ
subtype/NN
and/CC
patient/NN
age/NN
are/VBP
strongly/RB
associated/VBN
with/IN
clinical/JJ
features/NNS
,/,
such/JJ
as/IN
survival/NN
rate/NN
./.
====================
Fredholm/JJ
et/FW
al/JJ
./.
====================
[/(
14/CD
]/)
reported/VBD
that/IN
the/DT
5-year/JJ
survival/NN
rate/NN
was/VBD
lowest/RBR
in/IN
the/DT
of/IN
25–34-year-old/JJ
age/NN
group/NN
and/CC
decreased/VBD
with/IN
increasing/VBG
age/NN
./.
====================
Likewise/RB
,/,
Gnerlich/JJ
et/FW
al/JJ
./.
====================
[/(
15/CD
]/)
reported/VBD
that/IN
younger/JJR
women/NNS
were/VBD
more/RBR
likely/JJ
to/TO
die/VB
from/IN
breast/NN
cancer/NN
than/IN
older/JJR
ones/NNS
,/,
based/VBN
on/IN
the/DT
statistics/NNS
of/IN
243,012/NN
breast/NN
cancer/NN
patients/NNS
./.
====================
Recently/RB
,/,
Azim/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
studied/VBN
genomic/JJ
aberrations/NNS
in/IN
young/JJ
and/CC
elderly/JJ
breast/NN
cancer/NN
patients/NNS
based/VBN
on/IN
TCGA/NN
data/NNS
./.
====================
They/PRP
found/VBN
that/IN
older/JJR
patients/NNS
had/VBD
more/RBR
somatic/JJ
mutations/NNS
and/CC
copy/NN
number/NN
variations/NNS
(/(
CNVs/NNS
)/)
and/CC
that/IN
11/CD
mutations/NNS
and/CC
two/CD
CNVs/NNS
were/VBD
independently/RB
associated/VBN
with/IN
age/NN
at/IN
diagnosis/NN
./.
====================
In/IN
this/DT
work/NN
,/,
we/PRP
aimed/VBD
to/TO
classify/VB
human/JJ
genes/NNS
based/VBN
on/IN
age-specific/JJ
differential/JJ
expression/NN
between/IN
normal/JJ
and/CC
breast/NN
cancer/NN
cells/NNS
./.
====================
DEGs/NNS
were/VBD
identified/VBN
based/VBN
on/IN
their/PRP$
p-values/NNS
for/IN
differential/JJ
gene/NN
expression/NN
between/IN
tumor/NN
and/CC
matched/VBN
normal/JJ
cells/NNS
./.
====================
DEGs/NNS
and/CC
non-DEGs/NNS
were/VBD
then/RB
classified/VBD
based/VBN
on/IN
age-specific/JJ
differential/JJ
expression/NN
by/IN
the/DT
three/CD
age/NN
groups/NNS
we/PRP
defined/VBD
./.
====================
To/TO
show/VB
an/DT
application/NN
of/IN
the/DT
classification/NN
,/,
we/PRP
compared/VBD
the/DT
accuracy/NN
of/IN
prediction/NN
models/NNS
that/DT
distinguish/VBP
normal/JJ
and/CC
tumor/NN
cells/NNS
,/,
constructed/VBN
by/IN
support/VBP
vector/NN
machine/NN
(/(
SVM/NN
)/)
using/VBG
various/JJ
combinations/NNS
of/IN
genes/NNS
by/IN
class/NN
./.
====================
The/DT
performance/NN
of/IN
SVM/NN
was/VBD
measured/VBN
by/IN
the/DT
average/NN
area/NN
under/IN
the/DT
receiver/NN
operating/VBG
characteristics/NNS
curve/VBP
value/NN
after/IN
1,000/CD
times/NNS
bootstrap/JJ
./.
====================
All/DT
gene/NN
expression/NN
values/NNS
in/IN
this/DT
work/NN
were/VBD
gathered/VBN
from/IN
TCGA/NN
./.
====================
Eligible/JJ
patients/NNS
had/VBD
complete/JJ
clinical/JJ
data/NNS
and/CC
a/DT
gene/NN
expression/NN
dataset/NN
of/IN
breast/NN
cancer/NN
cells/NNS
and/CC
matched/VBN
normal/JJ
cells/NNS
./.
====================
Eventually/RB
,/,
we/PRP
retrieved/VBD
the/DT
gene/NN
expression/NN
values/NNS
of/IN
tumor/NN
and/CC
matched/VBN
normal/JJ
cells/NNS
of/IN
96/CD
patients/NNS
./.
====================
The/DT
distribution/NN
of/IN
their/PRP$
ages/NNS
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
The/DT
values/NNS
for/IN
gene/NN
expression/NN
level/NN
that/IN
we/PRP
used/VBD
were/VBD
generated/VBN
by/IN
the/DT
Illumina/NN
Hi-Seq/JJ
platform/NN
(/(
Illumina/NN
,/,
Inc./NNP
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
normalized/VBD
by/IN
root/NN
square/VBP
error/NN
methods/NNS
[/(
17/CD
]/)
./.
====================
All/DT
subsequent/JJ
statistical/JJ
analyses/NNS
were/VBD
carried/VBN
out/RP
using/VBG
R/NN
,/,
version/NN
3.2.3/CD
./.
====================
SVM/NN
classifiers/NNS
were/VBD
constructed/VBN
using/VBG
the/DT
e1071/NN
package/NN
of/IN
R/NN
,/,
and/CC
a/DT
simple/JJ
linear/NN
kernel/NN
was/VBD
used/VBN
./.
====================
Functional/JJ
enrichment/JJ
analysis/NN
of/IN
gene/NN
classes/NNS
was/VBD
performed/VBN
in/IN
ToppGene/NN
Suite/NN
[/(
18/CD
]/)
./.
====================
Young/NN
patients/NNS
were/VBD
defined/VBN
as/IN
≤45/CD
years/NNS
of/IN
age/NN
,/,
and/CC
elderly/JJ
patients/NNS
were/VBD
defined/VBN
as/IN
those/DT
≥60/CD
years/NNS
of/IN
age/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
rest/JJS
of/IN
the/DT
patients/NNS
were/VBD
defined/VBN
as/IN
“/RB
intermediate./FW
”/CD
The/DT
statistical/JJ
significance/NN
of/IN
differential/JJ
expression/NN
between/IN
tumor/NN
and/CC
matched/VBN
normal/JJ
cells/NNS
was/VBD
determined/VBN
by/IN
paired/JJ
t/NN
test/NN
,/,
based/VBN
on/IN
a/DT
p-value/JJ
threshold/JJ
of/IN
8.48/CD
×/CD
10−7/CD
./.
====================
The/DT
threshold/JJ
value/NN
was/VBD
set/NN
based/VBN
on/IN
the/DT
Bonferroni/NN
correction/NN
,/,
because/IN
a/DT
test/NN
was/VBD
performed/VBN
for/IN
each/DT
age/NN
group/NN
,/,
and/CC
three/CD
age/NN
groups/NNS
were/VBD
defined/VBN
for/IN
each/DT
of/IN
the/DT
19,646/CD
genes/NNS
./.
====================
The/DT
overall/JJ
scheme/NN
of/IN
our/PRP$
classification/NN
is/VBZ
depicted/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
We/PRP
first/RB
divided/VBN
genes/NNS
into/IN
two/CD
classes/NNS
(/(
A/NN
and/CC
B/NN
)/)
by/IN
paired/JJ
t/NN
test/NN
without/IN
considering/VBG
age/NN
./.
====================
A/DT
total/JJ
of/IN
5,962/CD
genes/NNS
in/IN
class/NN
A/DT
were/VBD
defined/VBN
as/IN
significant/JJ
DEGs/NNS
in/IN
breast/NN
cancer/NN
,/,
and/CC
13,684/CD
in/IN
class/NN
B/NN
were/VBD
nonsignificant/JJ
./.
====================
Ones/NNS
who/WP
want/JJ
to/TO
find/VB
biomarkers/NNS
or/CC
driver/RB
genes/NNS
are/VBP
likely/JJ
to/TO
investigate/VB
only/RB
genes/NNS
in/IN
class/NN
A/DT
./.
====================
However/RB
,/,
we/PRP
classified/VBD
the/DT
genes/NNS
of/IN
each/DT
class/NN
once/RB
again/RB
into/IN
eight/CD
groups/NNS
,/,
based/VBN
on/IN
the/DT
pattern/NN
of/IN
p-values/NNS
,/,
which/WDT
were/VBD
calculated/VBN
separately/RB
for/IN
every/RB
age/NN
group/NN
(/(
secondary/JJ
classification/NN
in/IN
Fig/NN
./.
====================
2/CD
)/)
./.
====================
After/IN
a/DT
second/JJ
round/NN
of/IN
classification/NN
,/,
the/DT
genes/NNS
were/VBD
eventually/RB
divided/VBN
into/IN
16/CD
classes/NNS
(/(
A1–B8/NN
)/)
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
The/DT
numbers/NNS
of/IN
genes/NNS
of/IN
the/DT
classes/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
It/PRP
was/VBD
easily/RB
observed/VBN
that/IN
there/EX
was/VBD
no/DT
gene/NN
classified/VBN
as/IN
class/NN
B1/NN
./.
====================
Probably/RB
,/,
this/DT
was/VBD
because/IN
the/DT
significance/NN
of/IN
genes/NNS
in/IN
class/NN
B/NN
was/VBD
already/RB
tested/VBN
in/IN
the/DT
primary/JJ
classification/NN
step/NN
,/,
and/CC
no/DT
genes/NNS
showed/VBD
significance/NN
over/IN
all/DT
age/NN
groups/NNS
./.
====================
The/DT
377/CD
genes/NNS
in/IN
class/NN
A1/NN
exhibited/VBD
differential/JJ
expression/NN
for/IN
every/RB
age/NN
group/NN
and/CC
all/DT
samples/NNS
./.
====================
These/DT
genes/NNS
are/VBP
the/DT
most/JJS
powerful/JJ
DEGs/NNS
between/IN
normal/JJ
and/CC
breast/NN
cancer/NN
cells/NNS
./.
====================
Genes/NNS
of/IN
class/NN
2/CD
,/,
which/WDT
did/VBD
not/RB
have/VB
significantly/RB
different/JJ
expression/NN
in/IN
any/DT
age/NN
group/NN
,/,
accounted/VBN
for/IN
the/DT
majority/NN
in/IN
both/DT
classes/NNS
A/DT
and/CC
B/NN
./.
====================
Indeed/RB
,/,
classes/NNS
1/CD
and/CC
2/CD
did/VBD
not/RB
have/VB
any/DT
age-specific/JJ
significance/NN
./.
====================
Thus/RB
,/,
we/PRP
focused/VBD
on/IN
the/DT
genes/NNS
of/IN
classes/NNS
3–8/CD
,/,
which/WDT
showed/VBD
age-specific/JJ
differential/JJ
expression/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Functional/JJ
enrichment/JJ
analysis/NN
for/IN
each/DT
class/NN
was/VBD
performed/VBN
,/,
but/CC
we/PRP
could/MD
not/RB
find/VB
any/DT
relevant/JJ
or/CC
intriguing/JJ
biological/JJ
implications/NNS
or/CC
pathways/NNS
related/JJ
to/TO
breast/NN
cancer/NN
./.
====================
Hence/RB
,/,
we/PRP
decided/VBD
to/TO
provide/VB
the/DT
results/NNS
of/IN
the/DT
analysis/NN
as/IN
raw/JJ
data/NNS
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
rather/RB
than/IN
trying/VBG
an/DT
unfeasible/JJ
deduction/NN
./.
====================
To/TO
show/VB
an/DT
example/NN
of/IN
how/WRB
the/DT
classification/NN
can/MD
be/VB
applied/VBN
,/,
we/PRP
constructed/VBD
prediction/NN
models/NNS
that/DT
aimed/VBD
to/TO
distinguish/VB
normal/JJ
and/CC
breast/NN
cancer/NN
cells/NNS
,/,
using/VBG
the/DT
expression/NN
values/NNS
of/IN
various/JJ
combinations/NNS
of/IN
genes/NNS
./.
====================
We/PRP
defined/VBD
two/CD
types/NNS
of/IN
combinations/NNS
comprising/VBG
gene/NN
lists/NNS
./.
====================
For/IN
type/NN
I/CD
combinations/NNS
,/,
genes/NNS
were/VBD
chosen/NN
evenly/RB
from/IN
each/DT
class/NN
./.
====================
By/IN
contrast/NN
,/,
genes/NNS
were/VBD
chosen/NN
randomly/RB
for/IN
type/NN
II/CD
combinations/NNS
without/IN
considering/VBG
gene/NN
class/NN
./.
====================
For/IN
example/NN
,/,
if/IN
we/PRP
make/VBP
a/DT
list/NN
composed/VBN
of/IN
three/CD
genes/NNS
from/IN
classes/NNS
3/CD
,/,
4/CD
,/,
and/CC
5/CD
,/,
the/DT
type/NN
I/CD
combination/NN
should/MD
consist/VB
of/IN
a/DT
gene/NN
from/IN
class/NN
3/CD
,/,
another/DT
from/IN
class/NN
4/CD
,/,
and/CC
the/DT
other/JJ
one/CD
from/IN
class/NN
5/CD
,/,
but/CC
a/DT
type/NN
II/CD
combination/NN
could/MD
be/VB
composed/VBN
of/IN
any/DT
genes/NNS
randomly/RB
chosen/NN
from/IN
the/DT
pool/NN
of/IN
the/DT
three/CD
classes/NNS
./.
====================
We/PRP
compared/VBD
the/DT
accuracies/NNS
of/IN
the/DT
SVM/NN
of/IN
type/NN
I/CD
and/CC
II/CD
combinations/NNS
for/IN
three/CD
subsets/NNS
each/DT
for/IN
classes/NNS
A/DT
and/CC
B/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
performance/NN
of/IN
type/NN
I/CD
was/VBD
significantly/RB
better/RBR
than/IN
that/DT
of/IN
type/NN
II/CD
,/,
except/IN
in/IN
two/CD
cases/NNS
(/(
classes/NNS
6–8/CD
in/IN
both/DT
classes/NNS
A/DT
and/CC
B/NN
)/)
,/,
the/DT
genes/NNS
of/IN
which/WDT
were/VBD
significantly/RB
differentially/RB
expressed/VBN
in/IN
the/DT
two/CD
age/NN
groups/NNS
./.
====================
These/DT
results/NNS
highlight/VBP
the/DT
value/NN
of/IN
gene/NN
classification/NN
based/VBN
on/IN
our/PRP$
method/NN
./.
====================
Based/VBN
on/IN
the/DT
first/JJ
classification/NN
,/,
13,684/CD
genes/NNS
in/IN
class/NN
B/NN
were/VBD
probably/RB
considered/VBN
genes/NNS
that/WDT
can/MD
not/RB
distinguish/VB
normal/JJ
and/CC
breast/NN
cancer/NN
cells/NNS
./.
====================
However/RB
,/,
by/IN
adapting/VBG
one/CD
more/RBR
classification/NN
step/NN
based/VBN
on/IN
age-specific/JJ
differential/JJ
expression/NN
,/,
we/PRP
identified/VBD
171/CD
age-specific/JJ
DEGs/NNS
in/IN
classes/NNS
B3–B8/NN
./.
====================
Despite/IN
the/DT
underestimated/JJ
value/NN
of/IN
the/DT
classes/NNS
,/,
we/PRP
showed/VBD
that/IN
a/DT
balanced/JJ
selection/NN
of/IN
genes/NNS
from/IN
these/DT
classes/NNS
could/MD
be/VB
applied/VBN
as/IN
biomarkers/NNS
,/,
identifying/VBG
breast/NN
cancer/NN
from/IN
normal/JJ
cells/NNS
./.
====================
For/IN
example/NN
,/,
genes/NNS
that/WDT
are/VBP
known/VBN
to/TO
be/VB
high-penetrance/RB
breast/NN
cancer/NN
susceptibility/NN
genes/NNS
,/,
such/JJ
as/IN
TP53/NN
,/,
STK11/NN
,/,
and/CC
CDH11/NN
,/,
and/CC
moderate-penetrance/NN
genes/NNS
,/,
such/JJ
as/IN
RAD50/NN
,/,
RAD51C/NN
,/,
RAD51D/NN
,/,
NBS1/NN
,/,
and/CC
FANCM/NN
,/,
were/VBD
classified/VBN
in/IN
class/NN
B2/NN
[/(
19/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
proposing/VBG
the/DT
possibility/NN
of/IN
genes/NNS
in/IN
class/NN
B/NN
as/IN
biomarkers/NNS
,/,
even/RB
for/IN
class/NN
A/DT
,/,
we/PRP
exhibited/VBD
that/DT
our/PRP$
method/NN
of/IN
selecting/VBG
biomarker/NN
genes/NNS
based/VBN
on/IN
secondary/JJ
classification/NN
could/MD
be/VB
useful/JJ
in/IN
making/VBG
a/DT
combination/NN
of/IN
biomarker/NN
genes/NNS
for/IN
a/DT
more/RBR
accurate/JJ
prediction/NN
by/IN
using/VBG
different/JJ
classes/NNS
complementarily/RB
./.
====================
In/IN
summary/NN
,/,
we/PRP
retrieved/VBD
a/DT
gene/NN
expression/NN
dataset/NN
of/IN
breast/NN
cancer/NN
and/CC
matched/VBN
normal/JJ
cells/NNS
from/IN
TCGA/NN
and/CC
then/RB
classified/VBN
the/DT
genes/NNS
into/IN
16/CD
classes/NNS
by/IN
two-step/JJ
classification/NN
./.
====================
This/DT
classification/NN
could/MD
be/VB
applied/VBN
to/TO
generate/VB
a/DT
more/RBR
accurate/JJ
prediction/NN
model/NN
for/IN
identifying/VBG
cancer/NN
./.
====================
Furthermore/RB
,/,
we/PRP
expect/VBP
that/DT
our/PRP$
scheme/NN
of/IN
classification/NN
could/MD
be/VB
used/VBN
for/IN
other/JJ
types/NNS
of/IN
cancer/NN
data/NNS
./.
====================
Distribution/NN
of/IN
age/NN
of/IN
breast/NN
cancer/NN
patients/NNS
analyzed/VBD
in/IN
this/DT
work/NN
./.
====================
Schematic/JJ
view/NN
of/IN
overall/JJ
procedures/NNS
of/IN
the/DT
two-step/JJ
classification/NN
./.
====================
Patterns/NN
of/IN
significance/NN
of/IN
age-specific/JJ
differential/JJ
expression/NN
of/IN
class/NN
A/DT
(/(
A/NN
)/)
and/CC
class/NN
B/NN
(/(
B/NN
)/)
./.
====================
Definition/NN
of/IN
classification/NN
of/IN
genes/NNS
based/VBN
on/IN
age-specific/JJ
significance/NN
and/CC
the/DT
corresponding/JJ
number/NN
of/IN
genes/NNS
====================
Comparison/NN
of/IN
performance/NN
of/IN
SVM/NN
models/NNS
of/IN
different/JJ
combinations/NNS
of/IN
genes/NNS
to/TO
distinguish/VB
breast/NN
cancer/NN
and/CC
normal/JJ
cells/NNS
====================
